Aripiprazole Tablet, Orally Disintegrating
Product Images NDC 62332-104

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 62332-104). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Aripiprazole Str)

Chemical structure of Aripiprazole, illustrating the molecular arrangement including two chlorine atoms on a phenyl ring and various connected rings and functional groups.*

FDA Label Image

Figure 1 (Aripiprazole 1figure)

This chart illustrates the effect of various drugs on the pharmacokinetics (AUC and Cmax) of Aripiprazole, showing fold change and 90% confidence intervals. It compares CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs relative to a reference without interacting drugs.*

FDA Label Image

Figure 2 (Aripiprazole 2figure)

A pharmacokinetic plot showing the effect of various drugs on Aripiprazole's dehydro-aripiprazole levels. The graph compares fold changes and 90% confidence intervals for AUC and Cmax values relative to a reference without interacting drugs. Drugs included are CYP3A4 and CYP2D6 inhibitors, CYP3A4 inducer, gastric acid blockers, and others like valproate, lithium, and lorazepam.*

FDA Label Image

Figure 3 (Aripiprazole Figure3)

A forest plot chart depicting fold change and 90% confidence intervals for pharmacokinetic parameters (AUC, Cmax, NR) of various drugs and enzymes relative to a reference without interacting drug. The y-axis lists drug names and enzymes, while the x-axis shows change relative to reference from 0 to 3 fold. Each plotted point includes error bars representing confidence intervals.*

FDA Label Image

Figure 4 (Aripiprazole 4figure)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing changes in AUC and Cmax relative to reference values for various special populations, including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The horizontal axis represents change relative to reference, with data points and confidence intervals for each subcategory.*

FDA Label Image

Figure 5 (Aripiprazole 5figure)

A pharmacokinetic chart depicting fold changes and 90% confidence intervals of Dehydro-Aripiprazole for various factors including CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and severe renal impairment. The graph shows changes relative to a reference for AUC and Cmax parameters with data points and error bars along a horizontal axis scaled from 0 to 3.*

FDA Label Image

Figure 6 (Aripiprazole Figure 6)

A Kaplan-Meier survival curve chart showing the proportion of subjects with relapse over 182 days from randomization. It compares two groups: Aripiprazole and placebo. The chart includes the number of subjects at risk for each group at various time points along the x-axis (days). Aripiprazole is represented by a solid line, and placebo by a dashed line.*

FDA Label Image

Figure 7 (Aripiprazole Fig 7)

A Kaplan-Meier survival plot comparing the proportion of subjects with relapse over 182 days from randomization between Aripiprazole and placebo groups. The plot includes a step curve for each group and a table showing the number of subjects at risk at various time points. The Aripiprazole group shows a consistently lower proportion of relapse compared to placebo.*

FDA Label Image

Figure 9 (Aripiprazole 9 Figure)

A line graph depicting the least squares mean change in YGTSS total TIC score from baseline over 8 weeks of treatment for three groups: Aripiprazole low dose, Aripiprazole high dose, and placebo. The x-axis represents weeks of treatment, and the y-axis shows the change in YGTSS total TIC score, with decreases indicating improvement.*

FDA Label Image

30tablets (Aripiprazole mg10)

Label for Aripiprazole Orally Disintegrating Tablets, USP 10 mg by Alembic Pharmaceuticals Inc. The carton displays the product name, strength, dosage form, and a quantity of 30 tablets (3 x 10 unit dose). It includes barcodes and states 'Rx only' with a pharmacist dispensing note.*

FDA Label Image

30 Tablets (3 X 10 Unit Dose) (Aripiprazole mg 15)

The packaging label for Aripiprazole Orally Disintegrating Tablets, USP, 15 mg by Alembic Pharmaceuticals Inc. It displays the tablet strength as 15 mg and indicates the package contains 30 tablets (10 units per dose). The label includes the NDC number 62332-104-30 and notes the product is prescription only with a reminder to dispense with the medication guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.